Search Results

June 1, 2015

Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

Oral presentation (abstract 10503) featured at the Annual Meeting of the American Society of Clinical Oncology

May 28, 2015

New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Janssen Expands EXPLORER Cardiovascular Research Program to Include New, Multi-Trial, Prospective Research Program Aimed at Generating New Evidence in Treating and Preventing Cancer-Associated Blood Clots

Innovative Medicine

May 22, 2015

Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia

A rare B-cell lymphoma with no EMA-approved treatment options available

Innovative Medicine

May 19, 2015

U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia

93% of patients treated with INVEGA TRINZA™ remained relapse-free at the end of long-term maintenance trial

Innovative Medicine

April 15, 2015

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

Innovative Medicine

April 8, 2015

Janssen Highlights Hepatitis C Virus Development Program at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

Presentations include late-breaking final results from the Phase 3 OPTIMIST trials and interim results from the Phase 2 IMPACT trial of simeprevir

Innovative Medicine

February 11, 2015

Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF

Unique Approach Aims to Intercept Disease Prior to Onset and Preserve Health of People At-risk of Developing Type 1 Diabetes

Innovative Medicine

January 30, 2015

PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1

Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen

Innovative Medicine

January 29, 2015

U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia: First FDA-Approved Therapy for This Disease

Approval represents fourth indication for IMBRUVICA in the U.S.

Innovative Medicine

January 19, 2015

FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine